Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan

Mitsuyoshi Tanishima, Kayo Ibaraki, Keishi Kido, Shun Nakayama, Kohei Ata, Hideki Nakamura, Yasuhiko Shinmura, Masafumi Endo, Kengo Sonoda, Kohji Ueda, Yoshiaki Oda
doi: https://doi.org/10.1101/2022.06.28.22276794

Article Information

doi 
https://doi.org/10.1101/2022.06.28.22276794
History 
  • June 29, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Mitsuyoshi Tanishima1,*,
  2. Kayo Ibaraki1,
  3. Keishi Kido1,
  4. Shun Nakayama1,
  5. Kohei Ata1,
  6. Hideki Nakamura1,
  7. Yasuhiko Shinmura1,
  8. Masafumi Endo1,
  9. Kengo Sonoda1,
  10. Kohji Ueda2 and
  11. Yoshiaki Oda1
  1. 1KM Biologics Co., Ltd. (KM Biologics), Kumamoto, Japan
  2. 2Professor emeritus, Kyushu University, Fukuoka, Japan
  1. ↵*CORRESPONDANCE
    Mitsuyoshi Tanishima, KM Biologics Co., Ltd (KM Biologics), 869-1298 Kumamoto, Japan. Email: tanishima-mi{at}kmbiologics.com
Back to top
Posted June 29, 2022.
Download PDF
Data/Code
Email
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan
Mitsuyoshi Tanishima, Kayo Ibaraki, Keishi Kido, Shun Nakayama, Kohei Ata, Hideki Nakamura, Yasuhiko Shinmura, Masafumi Endo, Kengo Sonoda, Kohji Ueda, Yoshiaki Oda
medRxiv 2022.06.28.22276794; doi: https://doi.org/10.1101/2022.06.28.22276794
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area